Revenue
2022
2023
2024
2025
Zentalis Pharmaceuticals, Inc. (ZNTL)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $67.4M | $0 | $0 | — | — | — |
| Research & development | $107.3M | $167.8M | $189.6M | $172.7M | $175.6M | $84.9M | $38.4M |
| Operating expenses | $152.8M | $258.6M | $299.5M | $227.3M | $216.5M | $118.8M | $46.8M |
| Operating income | −$152.8M | −$191.2M | −$299.5M | −$227.3M | −$216.5M | −$118.8M | −$46.8M |
| EBITDAderived | −$152.1M | −$189.9M | −$298.1M | −$225.9M | −$216.0M | −$118.6M | −$46.7M |
| Net income | −$137.1M | −$165.8M | −$292.2M | −$236.8M | −$158.7M | −$117.8M | −$45.7M |
| Basic EPSper diluted share | -$1.91 | -$2.33 | -$4.47 | -$4.48 | -$3.72 | -$4.19 | — |
| Diluted EPSper diluted share | -$1.91 | -$2.33 | -$4.47 | -$4.48 | -$3.72 | -$4.19 | -$8.16 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 10, 2026Form 4 · 10b5-1 | Vultaggio VincentPAO and PFO | SellCommon Stock | 6.9K | $2.42 | $16.7K | 146.5K |
| Feb 9, 2026Form 4 · 10b5-1 | Vultaggio VincentPAO and PFO | SellCommon Stock | 3.4K | $2.39 | $8.1K | 153.4K |
| Feb 9, 2026Form 4 | Bruns IngmarChief Medical Officer | SellCommon Stock | 335 | $2.39 | $800.65 | 33.3K |
| Feb 9, 2026Form 4 | EASTLAND JULIA MARIECEO & President | SellCommon Stock | 889 | $2.39 | $2.1K | 79.1K |
| Feb 6, 2026Form 4 · 10b5-1 | Vultaggio VincentPAO and PFO | SellCommon Stock | 30.0K | $2.43 | $72.8K | 156.8K |